Post Submission Regulatory Services
Navigating Post Submission Challenges with Seamless Transition from Submission to Approval
We ensure compliance & enhance safety by our post submission services
We offers comprehensive post-submission regulatory services to help pharmaceutical manufacturers fulfil their regulatory responsibilities, monitor product performance, and address any new compliance concerns, ensuring continuous adherence and preservation of market authorization for medical devices, pharmaceuticals, biologics, and IVD products.
Post submission services involve activities after a product receives initial approval, ensuring on-going compliance with regulatory requirements, product safety, and managing any changes or updates throughout the product’s lifecycle, which are crucial for maintaining product safety.
Our team of experienced regulatory specialists offers post submission services to manufacturers, utilizing our extensive knowledge of various regulatory frameworks and regions to ensure compliance and successful implementation of regulatory tactics.
- We offer wide range of services that meets to your timely demands.
- Why Choose Zenovel ?
- Expert Regulatory Support
Access to a team of regulatory professionals with global expertise in post-submission processes and tailored solutions to address specific regulatory challenges.
- Proactive Compliance Management
Proactively monitor and implement updates to stay ahead of regulatory changes, while reducing non-compliance and potential regulatory actions through continuous monitoring and risk management.
- Streamlined Process
Utilize advanced tools and technologies to streamline post-submission regulatory activities, ensuring efficiency and accuracy.
- Within Budget Solution
Expertise and infrastructure can optimize resource allocation and reduce overhead costs, while focusing on core business activities and managing post-submission regulatory requirements.
- Improved Safety and Quality
Through rigorous post-market surveillance and quality management practices, promptly addressing potential risks to protect patient safety and maintain market confidence
People Also Ask (FAQs)
Post submission services refer to regulatory support provided after a product dossier has been submitted to health authorities. These services include regulatory response management, addressing health authority queries, submission updates, and regulatory compliance support to ensure the approval process continues smoothly.
Post submission regulatory services help pharmaceutical companies effectively manage communications with regulatory authorities. They support query responses, regulatory submission updates, and variation submissions, ensuring that regulatory requirements are met and approval timelines are maintained.
Post-submission regulatory support includes responding to authority queries, preparing additional documents, managing variations, updating dossiers, and maintaining compliance. Zenovel supports these activities by ensuring timely responses, accurate documentation, and continuous regulatory alignment throughout the product lifecycle.
Efficient post submission lifecycle management services ensure that regulatory queries are addressed quickly and accurately. Proper handling of health authority responses, documentation updates, and regulatory clarification requests helps reduce approval delays and increases the chances of successful product registration.
Zenovel provides comprehensive post submission regulatory services, including health authority query management, regulatory submission updates, variation filing support, and ongoing regulatory compliance management. Their regulatory experts help pharmaceutical companies efficiently manage post-approval regulatory requirements across global markets.
Blogs and news
Our Latest Article
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
